Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Equity Residential, based in Chicago, is one of the largest apartment real estate investment trusts in the U.S. The company focuses on high-quality properties in large coastal cities in four core states, and average rental rates are about $3,000. About 30% of the portfolio is in California and 20% is in New York and Boston. EQR owns or has interests in 304 properties with about 80,000 apartment units, and 96% of assets are wholly owned. The tenant base consists mainly of affluent, single professionals. The shares are a component of the S&P 500. The company's market cap is about $24.5 billion.

Equity Residential owns a portfolio of 308 apartment communities with around 80,000 units and is developing four additional properties with 1,207 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.

MID-AMERICA APARTMENT COMM has an Investment Rating of HOLD; a target price of $161.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of High.